Company intelligence / Profile preview
Lab-to-Medi CRO
- Ownership
- Private
- Development stage
- Other
Overview
Lab-to-Medi CRO is a South Korean contract research organization (CRO) and biotechnology company founded in 2020 by Dr. Bo Sun Joo. The company provides comprehensive clinical trial services, regulatory affairs consulting, and data management for pharmaceuticals, health functional foods, cosmetics, and medical devices. In addition to its CRO services, Lab-to-Medi CRO conducts active research and development in biomaterials, specifically focusing on computer-aided design of visfatin-derived angiogenic peptides (such as Vis-1 and Vis-2) for applications in wound healing, skin regeneration, and ovarian function improvement.
- Therapeutic areas
- Women's HealthDermatology
- Modalities
- PeptidesBiologic
- Industry
- Contract Research Organization
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Lab-to-Medi CRO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lab-to-Medi CRO.